A House Democrat introduced articles of impeachment against Health and Human Services Secretary Robert F. Kennedy Jr., alleging abuses of authority and actions that undermine public‑health programs, including cuts to vaccine funding and personnel changes at CDC. The move is politically charged and unlikely to succeed given Republican control of Congress, but it formalizes dissent among lawmakers over HHS policy shifts. The filing cites specific operational decisions—staff reductions at CDC, cancellation of mRNA vaccine funding, and disputed regulatory approvals—as the basis for accountability. The development has prompted heightened scrutiny of HHS vaccine and public‑health policy and may influence agency relations with scientific and regulatory communities. For biotech and public‑health stakeholders, the episode increases uncertainty around federal vaccine policy, funding flows and regulatory continuity; companies relying on HHS programs or grants will monitor outcomes for potential programmatic and policy implications.